↓ Skip to main content

Cochrane Database of Systematic Reviews

Trifluoperazine versus placebo for schizophrenia

Overview of attention for article published in Cochrane database of systematic reviews, January 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

blogs
1 blog
twitter
16 tweeters
weibo
1 weibo user
facebook
1 Facebook page
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
200 Mendeley
Title
Trifluoperazine versus placebo for schizophrenia
Published in
Cochrane database of systematic reviews, January 2014
DOI 10.1002/14651858.cd010226.pub2
Pubmed ID
Authors

Kai Koch, Kamel Mansi, Euan Haynes, Clive E Adams, Stephanie Sampson, Vivek A Furtado

Abstract

Trifluoperazine is a long-established high potency typical antipsychotic drug used in the treatment of schizophrenia and schizophrenia-like illnesses.

Twitter Demographics

The data shown below were collected from the profiles of 16 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 200 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 1%
Unknown 198 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 45 23%
Student > Bachelor 29 14%
Researcher 24 12%
Student > Ph. D. Student 23 12%
Student > Doctoral Student 12 6%
Other 23 12%
Unknown 44 22%
Readers by discipline Count As %
Medicine and Dentistry 52 26%
Nursing and Health Professions 24 12%
Psychology 23 12%
Pharmacology, Toxicology and Pharmaceutical Science 12 6%
Social Sciences 8 4%
Other 30 15%
Unknown 51 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 August 2020.
All research outputs
#1,269,619
of 18,915,748 outputs
Outputs from Cochrane database of systematic reviews
#3,135
of 11,890 outputs
Outputs of similar age
#18,861
of 285,693 outputs
Outputs of similar age from Cochrane database of systematic reviews
#50
of 170 outputs
Altmetric has tracked 18,915,748 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,890 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.8. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,693 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 170 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.